Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

December 1, 2012

Universal City, California

Continuing Medical Education


Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum of 6.0 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for medical, radiation, and surgical oncologists, clinical nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the diagnosis and management of melanoma.

Learning Objectives

After completing this activity, participants should be able to: Demonstrate increased knowledge regarding:

  • Clinical utility of oncogene testing in melanoma
  • Current recommendations for radical lymph node dissection in melanoma patients with micrometastases in sentinel lymph nodes
  • Recent advances in targeted therapies for BRAF-mutant melanoma
  • Benefits and risks of immunotherapeutic approaches including anti-CTLA4 and anti-PD1 antibodies for management of melanoma
  • Use of combined modality regimens for melanoma patients
  • Molecular mechanisms involved in the development of basal cell carcinoma (BCC) and the novel targeted approaches for treatment of advanced disease

Feel more confident in their ability to:

  • Choose appropriate adjuvant therapy regimen for their patients with advanced melanoma
  • Optimize clinical benefit with anti-CTLA4 antibody in the treatment of melanoma
  • Select appropriate treatment strategies for a patient with BRAF-mutant melanoma
  • Treat advanced BCC patients with Hedgehog inhibitors
  • Obtain supplemental insurance coverage for evidence-based therapeutic choices in managing their patients